DOCSLIB.ORG

Biometrics and Biosecurity

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Biometrics and Biosecurity Journal of Biomedicine and Biotechnology Biometrics and Biosecurity Guest Editors: Tai-hoon Kim, Sabah Mohammed, Carlos Ramos, Osvaldo Gervasi, Wai-Chi Fang, and Adrian Stoica Biometrics and Biosecurity Journal of Biomedicine and Biotechnology Biometrics and Biosecurity Guest Editors: Tai-hoonKim, Sabah Mohammed, Carlos Ramos, Osvaldo Gervasi, Wai-Chi Fang, and Adrian Stoica Copyright © 2012 Hindawi Publishing Corporation. All rights reserved. This is a speacial issue published in “Journal of Biomedicine and Biotechnology.” All articles are open access articles distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Editorial Board The editorial board of the journal is organized into sections that correspond to the subject areas covered by the journal. Agricultural Biotechnology Ahmad Zuhairi Abdullah, Malaysia Hari B. Krishnan, USA B. C. Saha, USA Guihua H. Bai, USA Carol A. Mallory-Smith, USA Abdurrahman Saydut, Turkey Christopher P. Chanway, Canada Xiaoling Miao, China Mariam B. Sticklen, USA Ravindra N. Chibbar, Canada Dennis P. Murr, Canada Kok Tat Tan, Malaysia Adriana S. Franca, Brazil Rodomiro Ortiz, Sweden Chiu-Chung Young, Taiwan Ian Godwin, Australia Encarnacion´ Ruiz, Spain Animal Biotechnology E. S. Chang, USA Tosso Leeb, Switzerland Lawrence B. Schook, USA Bhanu P. Chowdhary, USA James D. Murray, USA Mari A. Smits, The Netherlands Noelle E. Cockett, USA Anita M. Oberbauer, USA Leon Spicer, USA Peter Dovc, Slovenia Jorge A. Piedrahita, USA J. Verstegen, USA Scott C. Fahrenkrug, USA Daniel Pomp, USA Matthew B. Wheeler, USA Dorian J. Garrick, USA Kent M. Reed, USA Kenneth L. White, USA Thomas A. Hoagland, USA Lawrence Reynolds, USA Biochemistry Robert Blumenthal, USA Paul W. Doetsch, USA Wen-Hwa Lee, USA David Ronald Brown, UK Hicham Fenniri, Canada Richard D. Ludescher, USA Saulius Butenas, USA Nick V. Grishin, USA George Makhatadze, USA Vittorio Calabrese, Italy J. Guy Guillemette, Canada Leonid Medved, USA Miguel Castanho, Portugal Paul W. Huber, USA Susan A. Rotenberg, USA Francis J. Castellino, USA Chen-Hsiung Hung, Taiwan Jason Shearer, USA Roberta Chiaraluce, Italy Michael Kalafatis, USA Andrei Surguchov, USA D. M. Clarke, Canada B. E. Kemp, Australia John B. Vincent, USA Francesca Cutruzzola,` Italy Phillip E. Klebba, USA Y. George Zheng, USA Bioinformatics T. Akutsu, Japan Stavros J. Hamodrakas, Greece Zhirong Sun, China Miguel A. Andrade, Germany Paul Harrison, USA Ying Xu, USA Mark Y. Borodovsky, USA George Karypis, USA Alexander Zelikovsky, USA Rita Casadio, Italy Guohui Lin, Canada Albert Zomaya, Australia Artem Cherkasov, Canada Satoru Miyano, Japan David Corne, UK Zoran Obradovic, USA Sorin Draghici, USA Florencio Pazos, Spain Biophysics Miguel Castanho, Portugal Ali A. Khraibi, Saudi Arabia S. B. Petersen, Denmark P. Bryant Chase, USA Rumiana Koynova, USA Peter Schuck, USA Kuo-Chen Chou, USA Serdar Kuyucak, Australia Claudio M. Soares, Portugal Rizwan Khan, India Jianjie Ma, USA Cell Biology Omar Benzakour, France Xudong Huang, USA Michael Sheetz, USA Sanford I. Bernstein, USA Anton M. Jetten, USA JamesL.Sherley,USA Phillip I. Bird, Australia Seamus J. Martin, Ireland G. S. Stein, USA Eric Bouhassira, USA Manuela Martins-Green, USA Richard Tucker, USA Mohamed Boutjdir, USA Shoichiro Ono, USA Thomas van Groen, USA Chung-Liang Chien, Taiwan George Perry, USA Andre Van Wijnen, USA Richard Gomer, USA M. Piacentini, Italy Steve Winder, UK Paul J. Higgins, USA George E. Plopper, USA Chuanyue Wu, USA Pavel Hozak, Czech Republic Lawrence Rothblum, USA Bin-Xian Zhang, USA Genetics Adewale Adeyinka, USA M. Ilyas Kamboh, USA Dharambir K. Sanghera, USA Claude Bagnis, France Feige Kaplan, Canada Michael Schmid, Germany J. Birchler, USA Manfred Kayser, The Netherlands Markus Schuelke, Germany Susan Blanton, USA Brynn Levy, USA Wolfgang Arthur Schulz, Germany BarryJ.Byrne,USA Xiao Jiang Li, USA Jorge Sequeiros, Portugal R. Chakraborty, USA Thomas Liehr, Germany Mouldy Sioud, Norway Domenico Coviello, Italy James M. Mason, USA Gary S. Stein, USA Sarah H. Elsea, USA Mohammed Rachidi, France Rongjia Zhou, China Celina Janion, Poland Raj S. Ramesar, South Africa J. Spencer Johnston, USA Elliot D. Rosen, USA Genomics Vladimir Bajic, Saudi Arabia J. Spencer Johnston, USA John V. Moran, USA Margit Burmeister, USA Vladimir Larionov, USA Yasushi Okazaki, Japan Settara Chandrasekharappa, USA Thomas Lufkin, Singapore Gopi K. Podila, USA Yataro D aigo, Japan John L. McGregor, France Momiao Xiong, USA Immunology Hassan Alizadeh, USA James D. Gorham, USA Kanury V. S. Rao, India Peter Bretscher, Canada Silvia Gregori, Italy Yair Reisner, Israel Robert E. Cone, USA Thomas Griffith, USA Harry W. Schroeder, USA TerryL.Delovitch,Canada Young S. Hahn, USA Wilhelm Schwaeble, UK Anthony L. DeVico, USA Dorothy E. Lewis, USA Nilabh Shastri, USA Nick Di Girolamo, Australia Bradley W. McIntyre, USA Yufang Shi, China Don Mark Estes, USA R. Lee Mosley, USA Piet Stinissen, Belgium Soldano Ferrone, USA Marija Mostarica-Stojkovic,´ Serbia Hannes Stockinger, Austria Jeffrey A. Frelinger, USA Hans Konrad Muller, Australia Graham R. Wallace, UK John Robert Gordon, Canada Ali Ouaissi, France Microbial Biotechnology Suraini Abd-Aziz, Malaysia Peter Coloe, Australia Paula Loureiro Paulo, Brazil Jozef Anne,´ Belgium Daniele Daffonchio, Italy BerndH.A.Rehm,NewZealand Nuri Azbar, Turkey Han de Winde, The Netherlands Alberto Reis, Portugal Yoav Bashan, Mexico Raf Dewil, Belgium Muthuswamy Sathishkumar, Singapore Marco Bazzicalupo, Italy Jose´ Domingos Fontana, Brazil Ramkrishna Sen, India Hakan Bermek, Turkey Petros Gikas, Greece Angela Sessitsch, Austria Nico Boon, Belgium Tom Granstrom, Finland Ya-Jie Tang, China Jose´ Luis Campos, Spain Ismail Kiran, Turkey Orhan Yenigun, Turkey Yinguang Chen, China Hongjuan Liu, China Eileen Hao Yu, UK Luca Simone Cocolin, Italy Yanhe Ma, China Microbiology D. Beighton, UK Roy Gross, Germany Isabel Sa-Correia,´ Portugal Steven R. Blanke, USA Hans-Peter Klenk, Germany P. L. C. Small, USA Stanley Brul, The Netherlands Abdelwahab Omri, Canada Michael Thomm, Germany Isaac K. O. Cann, USA Tanya Parish, UK H. C. van der Mei, The Netherlands Stephen K. Farrand, USA Gopi K. Podila, USA Schwan William, USA Alain Filloux, UK Frederick D. Quinn, USA Gad Frankel, UK Didier A. Raoult, France Molecular Biology Rudi Beyaert, Belgium David W. Litchfield, Canada Elena Orlova, UK Michael Bustin, USA Wuyuan Lu, USA Yeon-Kyun Shin, USA Douglas Cyr, USA Patrick Matthias, Switzerland William S. Trimble, Canada K. Iatrou, Greece John L. McGregor, France Lisa Wiesmuller, Germany Lokesh Joshi, Ireland S. L. Mowbray, Sweden Masamitsu Yamaguchi, Japan Yasushi Okazaki, Japan Oncology Colin Cooper, UK Daehee Kang, Republic of Korea Frank Pajonk, USA F. M. J. Debruyne, The Netherlands Abdul R. Khokhar, USA Waldemar Priebe, USA Nathan Ames Ellis, USA Rakesh Kumar, USA F. C. Schmitt, Portugal Dominic Fan, USA Macus Tien Kuo, USA Sonshin Takao, Japan Gary E. Gallick, USA Eric W. Lam, UK Ana Maria Tari, USA Daila S. Gridley, USA Sue-Hwa Lin, USA Henk G. Van Der Poel, The Netherlands Xin-yuan Guan, Hong Kong Kapil Mehta, USA Haodong Xu, USA Anne Hamburger, USA Orhan Nalcioglu, USA David J. Yang, USA Manoor Prakash Hande, Singapore P. J. Oefner, Germany Beric Henderson, Australia Allal Ouhtit, Oman Pharmacology Abdel A. Abdel-Rahman, USA Ayman El-Kadi, Canada Kennerly S. Patrick, USA M. Badr, USA Jeffrey Hughes, USA Vickram Ramkumar, USA StelvioM.Bandiera,Canada Kazim Husain, USA Michael J. Spinella, USA Ronald E. Baynes, USA Farhad Kamali, UK Quadiri Timour, France R. Keith Campbell, USA Michael Kassiou, Australia Todd W. Vanderah, USA Hak-Kim Chan, Australia Joseph J. McArdle, USA Val J. Watts, USA Michael D. Coleman, UK Mark J. McKeage, New Zealand David J. Waxman, USA J. Descotes, France Daniel T. Monaghan, USA Dobromir Dobrev, Germany T. Narahashi, USA Plant Biotechnology Prem L. Bhalla, Australia Metin Guru, Turkey Yong Pyo Lim, Republic of Korea J. R. Botella, Australia H. M. Haggman,¨ Finland Gopi K. Podila, USA Elvira G. De Mejia, USA Liwen Jiang, Hong Kong Ralf Reski, Germany Shi-You Ding, USA Pulugurtha B. Kirti, India Sudhir Sopory, India Toxicology Michael Aschner, USA Hartmut Jaeschke, USA Qaisar Mahmood, Pakistan Juergen Buenger, Germany Youmin James Kang, USA R. S. Tjeerdema, USA Michael L. Cunningham, USA M. Firoze Khan, USA Kenneth Turteltaub, USA Laurence D. Fechter, USA Pascal Kintz, France Brad Upham, USA Virology Nafees Ahmad, USA Fred Kibenge, Canada Ralf Wagner, Germany Edouard Cantin, USA Fenyong Liu, USA Jianguo Wu, China Ellen Collisson, USA Eric´ Rassart, Canada Decheng Yang, Canada Kevin M. Coombs, Canada Gerald G. Schumann, Germany Jiing-Kuan Yee, USA Norbert K. Herzog, USA Y.-C. Sung, Republic of Korea Xueping Zhou, China Tom Hobman, Canada Gregory Tannock, Australia Wen-Quan Zou, USA Shahid Jameel, India Contents Biometrics and Biosecurity, Tai-hoon Kim, Sabah Mohammed, Carlos Ramos, Osvaldo Gervasi, Wai-Chi Fang, and Adrian Stoica Volume 2012, Article ID 684815, 3 pages A Privacy-Preserved Analytical Method for eHealth Database with Minimized Information Loss, Ya-Ling Chen, Bo-Chao Cheng, Hsueh-Lin Chen, Chia-I Lin, Guo-Tan Liao, Bo-Yu Hou, and Shih-Chun Hsu Volume 2012, Article ID 521267, 9 pages Anatomy of Biometric Passports, Dominik Malcˇık´ and Martin Drahansky´ Volume 2012, Article ID 490362, 8 pages Advanced Pulse Oximetry System for Remote Monitoring and Management, Ju Geon Pak and Kee
Load more

Recommended publications
  • Cutaneous Manifestations of Systemic Diseases 428 C2 Notes Dr
    Cutaneous Manifestations of systemic diseases 428 C2 Notes Dr. Eman Almukhadeb Cutaneous Manifestations of systemic diseases Dr. Eman Almukhadeb CUTANEOUS MANIFESTATIONS OF DIABETES MELLITUS: Specific manifestations: 1 Cutaneous Manifestations of systemic diseases 428 C2 Notes Dr. Eman Almukhadeb 1. Diabetes dermopathy or “SHIN SPOTS”: Most common cutaneous manifestation of diabetes; M > F, males over age 50 years with long standing diabetes. They are: bilateral, symmetrical, atrophic red-brownish macules and patches, over the shins mainly but can occur at any sites, asymptomatic. There is no effective treatment. 2. Necrobiosis Lipoidica Diabeticorum (NLD): Patients classically present with single or multiple red-brown papules, which progress to sharply demarcated yellow-brown atrophic, telangiectatic erythematic plaques with a violaceous, irregular border. Usually it’s unilateral. Common sites include shins followed by ankles, calves, thighs and feet. Very atrophic plaque so any trauma will lead to ulceration, it occurs in about 35% of cases. Cutaneous anesthesia, hypohidrosis and partial alopecia can be found Pathology: Palisading granulomas containing degenerating collagen. The nonenzymatic glycosylation of dermal collagen and elastin will lead to degeneration of the collagen and atrophy (necrobiosis). 2 Cutaneous Manifestations of systemic diseases 428 C2 Notes Dr. Eman Almukhadeb Approximately 60% of NLD patients have diabetes and 20% have glucose intolerance. Conversely, up to 3% of diabetics have NLD, so if a patient has NLD its common that he is diabetic, but not every diabetic patient have NLD. (Important) Women are more affected than men. Treatment: Ulcer prevention (by avoiding trauma). No impact of tight glucose control on likelihood of developing NLD. There are multiple treatment options available and all of them reported to be effective: o Intralesional steroids o Systemic aspirin: 300mg/day and dipyridamole: 75 mg/day.
    [Show full text]
  • Overall Skin Tone and Skin-Lightening-Improving Effects with Oral Supplementation of Lutein and Zeaxanthin Isomers: a Double-Blind, Placebo‑Controlled Clinical Trial
    Journal name: Clinical, Cosmetic and Investigational Dermatology Article Designation: ORIGINAL RESEARCH Year: 2016 Volume: 9 Clinical, Cosmetic and Investigational Dermatology Dovepress Running head verso: Juturu et al Running head recto: L/Zi supplementation improves overall skin tone and skin lightening open access to scientific and medical research DOI: http://dx.doi.org/10.2147/CCID.S115519 Open Access Full Text Article ORIGINAL RESEARCH Overall skin tone and skin-lightening-improving effects with oral supplementation of lutein and zeaxanthin isomers: a double-blind, placebo-controlled clinical trial Vijaya Juturu1 Purpose: Carotenoids, especially lutein and zeaxanthin isomers (L/Zi), filter blue light and James P Bowman2 protect skin from environmental factors including high-energy sources. These carotenoids may be Jayant Deshpande1 able to block the formation of melanin pathways, decrease cytokines, and increase antioxidants. Subjects and methods: This is a randomized, double-blind, placebo-controlled clinical 1Department of Scientific and Clinical Affairs, OmniActive Health trial over a 12-week supplementation period. Fifty healthy people (50 healthy subjects were Technologies Inc., Morristown, NJ, recruited and 46 subjects completed the study) (males and females, age: 18–45 years) with 2 James P Bowman & Associates LLC, mild-to-moderate dry skin were included in this study. Skin type of the subjects was classified Loveland, OH, USA as Fitzpatrick skin type II–IV scale. Subjects were administered with either an oral dietary supplement containing 10 mg lutein (L) and 2 mg zeaxanthin isomers (Zi) (L/Zi: RR-zeaxanthin and RS (meso)-zeaxanthin) or a placebo daily for 12 weeks. The minimal erythemal dose and skin lightening (L*) were measured via the Chromameter®.
    [Show full text]
  • Éditeur Officiel Du Québec
    1 0 © Québec Official Publisher Updated to October 31, 2020 This document has official status. chapter P-29, r. 1 Regulation respecting food A G Food Products Act R I(chapter P-29, s. 40). CP U0- 4A2 L The fees prescribed in the Regulation have been indexed as of 1 April 2019 pursuant to the notice p9 T published in Part 1 (French) of the Gazette officielle du Québec of 16 March 2019, page 255. (ss. r U 1.3.6.1, 1.3.6.2, 1.3.6.3, 1.3.6.4, 1.3.6.5, 1.3.6.6, 1.3.6.7, 1.3.6.7.3, 1.3.6.7.4, 1.3.6.7.5, 1.3.6.7.6, i R 1.3.6.7.7, 1.3.6.7.8, 1.3.6.10, 1.3.6.12) Al L0 TABLEP1 OF CONTENTS R O2 CHAPTER 1 D0 GENERAL PROVISIONS U1 DIVISION 1.1 C6 APPLICATION — DEFINITIONS.................................................................... 1.1.1 T S DIVISION 1.2 — REGISTRATION................................................................................................ 1.2.1 F O DIVISION 1.3 O PERMIT D § 1.3.1. — General provisions.............................................................................. 1.3.1.1 § 1.3.2. — Categories of slaughterhouse permit.................................................. 1.3.2.1 § 1.3.3. — Categories of permits for plants for the preparation, conditioning or processing, for wholesale purposes, of meat or meat products intended for human consumption........................................................................................... 1.3.3.1 § 1.3.4. — Categories of dismembering plant permit........................................... 1.3.4.1 § 1.3.5. — Categories of permits to salvage inedible meat.................................. 1.3.5.1 § 1.3.5.A.
    [Show full text]
  • Safety Assessment of Punica Granatum (Pomegranate)-Derived Ingredients As Used in Cosmetics
    Safety Assessment of Punica granatum (Pomegranate)-Derived Ingredients as Used in Cosmetics Status: Draft Final Report for Panel Review Release Date: May 15, 2020 Panel Meeting Date: June 8-9, 2020 The Expert Panel for Cosmetic Ingredient Safety members are: Chair, Wilma F. Bergfeld, M.D., F.A.C.P.; Donald V. Belsito, M.D.; Curtis D. Klaassen, Ph.D.; Daniel C. Liebler, Ph.D.; James G. Marks, Jr., M.D.; Lisa A. Peterson, Ph.D.; Ronald C. Shank, Ph.D.; Thomas J. Slaga, Ph.D.; and Paul W. Snyder, D.V.M., Ph.D. The Cosmetic Ingredient Review (CIR) Executive Director is Bart Heldreth, Ph.D. This safety assessment was prepared by Christina L. Burnett, Senior Scientific Analyst/Writer, CIR. © Cosmetic Ingredient Review 1620 L St NW, Suite 1200 ◊ Washington, DC 20036-4702 ◊ ph 202.331.0651 ◊fax 202.331.0088 ◊ [email protected] Distributed for Comment Only -- Do Not Cite or Quote Commitment & Credibility since 1976 Memorandum To: Expert Panel for Cosmetic Ingredient Safety Members and Liaisons From: Christina L. Burnett, Senior Scientific Writer/Analyst , CIR Date: May 15, 2020 Subject: Draft Final Safety Assessment on Punica granatum (Pomegranate)-Derived Ingredients Enclosed is the Draft Final Report of the Safety Assessment of Punica granatum (Pomegranate)-Derived Ingredients as Used in Cosmetics. (It is identified as pomegr062020rep in the pdf document.) At the December meeting, the Panel issued a Revised Tentative Report with the conclusion that the following 8 ingredients are safe in the present practices of use and concentration described
    [Show full text]
  • PND Releases a 200+ Page Catalog for Vitanova Signature
    TM VITANOV A Signature America's Best Choice TM ® ® CREATING A HEALTHY WORLDTM CREATING A HEALTHY WORLDTM Pharmapex's Nutrition Department PHARMAPex’swww.Pharmapex.net NutritioN DEPARTMENT www. Pharmapex.net @2016, Pharmapex Group, All Rights Reserved. Toll-Free: 1.844.PHARMAPEX Fax: +1.619.881.0035 [email protected] MEGAFOOD CREATING A HEALTHY WORLD™ www.Pharmapex.net ® CREATING A HEALTHY WORLDTM Vitanova Signature America's Best Choice™ ™ A Product of Pharmapex's Nutrition Department Toll-Free: 1.844.PHARMAPEX Fax: +1.619.881.0035 [email protected] VITANOVA SIGNATURE™ CREATING A HEALTHY WORLD™ www.Pharmapex.net PHARMAPEX GROUP & NUTRITION INDUSTRY Pharmapex Group is a leader in manufacturing, supply, and distribution of nutritional supplements and medicated food products in the nutrition industry. Nutritional Supplements With nearly 200 SKU's and 150 products to choose from, we manufacture our high quality nutritional supplement products in a new state-of-the art 132,000 square feet, environmentally-friendly production facility. With new investments, this facility is able to blend up to 200,000 kilos, and produce up to 120 million tablets, 140 million capsules and 1 million bottles per month with its current equipment. These quality products range from Acai and Resveratrol to a number of proprietary products such as Heart-Cholesterol Support and Brain Formula to aide in boosting energy and focus. Major Product Classes: • Amino Acids • Nutrient Enhancer • Antioxidants • Organics • B-Complex • Personal Care • Cleansing & Fiber •
    [Show full text]
  • Terpenoids As Potential Geroprotectors
    antioxidants Review Terpenoids as Potential Geroprotectors Ekaterina Proshkina 1 , Sergey Plyusnin 1,2 , Tatyana Babak 1, Ekaterina Lashmanova 1, Faniya Maganova 3, Liubov Koval 1,2, Elena Platonova 1,2, Mikhail Shaposhnikov 1 and Alexey Moskalev 1,2,* 1 Laboratory of Geroprotective and Radioprotective Technologies, Institute of Biology, Komi Science Centre, Ural Branch, Russian Academy of Sciences, 28 Kommunisticheskaya st., 167982 Syktyvkar, Russia; [email protected] (E.P.); [email protected] (S.P.); [email protected] (T.B.); [email protected] (E.L.); [email protected] (L.K.); [email protected] (E.P.); [email protected] (M.S.) 2 Pitirim Sorokin Syktyvkar State University, 55 Oktyabrsky Prosp., 167001 Syktyvkar, Russia 3 Initium-Pharm, LTD, 142000 Moscow, Russia; [email protected] * Correspondence: [email protected]; Tel.: +7-8212-312-894 Received: 22 May 2020; Accepted: 14 June 2020; Published: 17 June 2020 Abstract: Terpenes and terpenoids are the largest groups of plant secondary metabolites. However, unlike polyphenols, they are rarely associated with geroprotective properties. Here we evaluated the conformity of the biological effects of terpenoids with the criteria of geroprotectors, including primary criteria (lifespan-extending effects in model organisms, improvement of aging biomarkers, low toxicity, minimal adverse effects, improvement of the quality of life) and secondary criteria (evolutionarily conserved mechanisms of action, reproducibility of the effects on different models, prevention of age-associated diseases, increasing of stress-resistance). The number of substances that demonstrate the greatest compliance with both primary and secondary criteria of geroprotectors were found among different classes of terpenoids. Thus, terpenoids are an underestimated source of potential geroprotectors that can effectively influence the mechanisms of aging and age-related diseases.
    [Show full text]
  • Influence of Skin Diseases on Fingerprint Quality and Recognition
    Chapter 12 Influence of Skin Diseases on Fingerprint Quality and Recognition Michal Dolezel, Martin Drahansky, Jaroslav Urbanek, Eva Brezinova and Tai-hoon Kim Additional information is available at the end of the chapter http://dx.doi.org/10.5772/51992 1. Introduction Fingerprint recognition belongs to one of the most often used biometric technologies world‐ wide. It is believed that fingerprints could be used for the recognition of a person in nearly any case; however there exist many cases, where the fingerprint recognition could not be used. There exist some influencing factors [1] that have an impact to the process of finger‐ print recognition, e.g. the environmental influences, dirtiness on finger or the sensor, elec‐ tromagnetic radiation or diseases. This chapter deals with the circumstances which influence the quality of fingerprints – we are limited on skin diseases here, further we ex‐ plain how we can evaluate the quality of the acquired fingerprint. The fingerprint recognition consists of five main steps (see Fig. 1) [2, 3, 4]: • Fingerprint acquirement – the fingerprint is scanned using a sensor (for sensor technologies see [1]), i.e. the physical human biometric attribute is digitized and transferred to the computer. • Image enhancement – this step is very important for further processing, because the quality of the fingerprint image could be enhanced here. There are several methods used for im‐ age quality enhancement – edge filters, filtering in frequency spectrum (after Fast Fourier Transform), Gabor filter, etc. • Thresholding – the image is normally acquired with 256 gray levels, but we need a binary representation. Using various thresholding schemes (e.g.
    [Show full text]
  • Research Article Influence of Skin Diseases on Fingerprint Recognition
    Hindawi Publishing Corporation Journal of Biomedicine and Biotechnology Volume 2012, Article ID 626148, 14 pages doi:10.1155/2012/626148 Research Article Influence of Skin Diseases on Fingerprint Recognition Martin Drahansky,1 Michal Dolezel,1 Jaroslav Urbanek,2 Eva Brezinova,3 and Tai-hoon Kim4 1 Faculty of Information Technology, Brno University of Technology, Bozetechova 2, 61266 Brno, Czech Republic 2 Faculty of Medicine and Dentistry, Palacky´ University and Faculty Hospital, I. P. Pavlova 6, 77520 Olomouc, Czech Republic 3 Faculty of Medicine, Masaryk University, Komensk´eho nam´ ˇest´ı 2, 66243 Brno, Czech Republic 4 Department of Multimedia Engineering, Hannam University, 133 Ojeong-dong, Daedeok-gu, Daejeon 306791, Republic of Korea Correspondence should be addressed to Martin Drahansky, drahan@fit.vutbr.cz Received 25 February 2012; Accepted 26 February 2012 Academic Editor: Sabah Mohammed Copyright © 2012 Martin Drahansky et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. There are many people who suffer from some of the skin diseases. These diseases have a strong influence on the process of fingerprint recognition. People with fingerprint diseases are unable to use fingerprint scanners, which is discriminating for them, since they are not allowed to use their fingerprints for the authentication purposes. First in this paper the various diseases, which might influence functionality of the fingerprint-based systems, are introduced, mainly from the medical point of view. This overview is followed by some examples of diseased finger fingerprints, acquired both from dactyloscopic card and electronic sensors.
    [Show full text]
  • Prevalence and Determinants of Vitamin a Status of Women During
    Distribution Agreement In presenting this thesis or dissertation as a partial fulfillment of the requirements for an advanced degree from Emory University, I hereby grant to Emory University and its agents the non-exclusive license to archive, make accessible, and display my thesis or dissertation in whole or in part in all forms of media, now or hereafter known, including display on the world wide web. I understand that I may select some access restrictions as part of the online submission of this thesis or dissertation. I retain all ownership rights to the copyright of the thesis or dissertation. I also retain the right to use in future works (such as articles or books) all or part of this thesis or dissertation. _____________________________ ______________ Victor Akelo Date: Approval Sheet MODIFIABLE DETERMINANTS OF VITAMIN A DEFICIENCY AMONG PREGNANT WOMEN PARTICIPATING IN THE MAMA SASHA COHORT STUDY OF VITAMIN A IN WESTERN KENYA By Victor Akelo, MPH Hubert Department of Global Health _________________________________________ [Chair’s signature] Amy Webb Girard, PhD Committee Chair _________________________________________ [Member’s signature] Paul S. Weiss, MS Committee Member _________________________________________ [Member’s signature] Deborah A. McFarland, PhD, MPH Committee Member 2 | Page Draft version 1.0 MODIFIABLE DETERMINANTS OF VITAMIN A DEFICIENCY AMONG PREGNANT WOMEN PARTICIPATING IN THE MAMA SASHA COHORT STUDY OF VITAMIN A IN WESTERN KENYA By Victor Akelo Master of Public Health Global Health (Infectious Diseases) Thesis
    [Show full text]
  • Carotenoids and Retinoids in Human Nutrition
    Crilical Reviews in Food Science and NUlrilion, 31 (liZ): 103-163 (1992) Carotenoids and Retinoids in Human Nutrition E-Siong Tee Division of Human Nutrition, Institute for Medical Research, 50588 Kuala Lumpur, Malaysia Referee: C. Y. Lee, Ph.D., Department of Food Science and Technology, Cornell University, Geneva, New York 14456 ABSTRACT: Since the discovery of vitamin A as a fat-soluble growth factor in thl~ early part of the century. research into carotenoids and retinoids has attracted the attention of many scientists. These two groups of compounds are still being actively studied all over the world since many gaps in knowledge exist and new frontiers are being pursued. Recent developments in studies into the possible roles of carotl~noids and retinoids beyond their classical functions in vision have created a great deal of excitement in the biomedical community. This review covers a wide range of topics pertaining to these two closely related compounds. Particular emphasis is given to the functions of these compounds and their roles in human nutrition. V2,rious aspects of vitamin A deficiency and ,tudies on carotenoids and retmoids in cancer development and prevention are reviewed in some detail. KEY WORDS: carotenoids. retinoids, human nutrition, vitamin A deficiency, cancer development and prevention. I. INTRODUCTION chemical synthesis are all more recent achieve­ ments, accomplished during the 20th century. Some 75 years ago, vitamin A was discov-­ ered as a fat-soluble growth factor present in liver Vitamin A, or retinol, is an essential nutrient and recognized as an essential biochemical for for man and all mammalian species since it can­ normal vision in man and animals.
    [Show full text]
  • E-Poster Presentations
    Turk J Int Med 2021 E-Poster Presentations Adult Still’s Disease Activation or A Case of Autoimmune Polyglan- EP001 EP002 COVID-19 Infection: A Case Report dular Syndrome Presenting with Latent Autoimmune Diabetes Şeyma ESENBUĞA1, Belkıs Nihan COŞKUN2, Altuğ GÜNER2, Zeynep YILMAZ BOZKURT2, Nihal LERMİ2, Yavuz PEHLİVAN2, Ediz DALKILIÇ2 Coşkun ATEŞ1, Yasemin ÜNSAL1, Ensar AYDEMİR1, Özen ÖZ GÜL1, Soner CANDER1, Canan ERSOY1, Erdinç ERTÜRK1 1Bursa Uludağ University Faculty of Medicine, Department of Internal Medicine, Bursa, Turkey 1Bursa Uludağ University Faculty of Medicine, Division of Endocrinology and 2Bursa Uludağ University Faculty of Medicine, Department of Internal Medicine, Metabolic Diseases, Bursa, Turkey Division of Rheumatology, Bursa, Turkey Background Adult Still’s Disease (ASD) is a systemic inflam- Background Autoimmune polyglandular syndrome (OPS) is matory disease manifested by fever, arthritis, and salmon-co- a group of autoimmune diseases characterized by the failure lored maculopapular rash. It may accompany pharyngitis, of at least two endocrine glands in hormone production. OPS splenomegaly, generalized lymphadenopathy, and serositis. In type 1 is seen in childhood and is diagnosed with hypoparath- the COVID-19 pandemic, COVID-19 findings can be confused yroidism, Addison’s disease, and candida infection involving with the exacerbation of ASD. We aimed to present a patient the skin or mucous membranes. OPS type 2 (Type 1 diabetes with a diagnosis of ASD who applied to our outpatient clinic with Addison’s disease or autoimmune thyroid disease), OPS type 3 (Autoimmune thyroid disease with other autoimmu- with fever and rash. ne diseases other than Addison) and OPS Type 4 (Addison’s Material and Methods A 50-year-old female patient diagnosed disease with one or more organ-specific Type 1 and type 2 with ASD in 2017 with complaints of common joint pain, fe- autoimmune diseases that do not include major components ver, rash, and sore throat was being followed up with predni- seen in OPS).
    [Show full text]
  • Appendix a Acid-Base Calculations
    Appendix A Acid-Base Calculations A. 1. IO NIC STRENGTH Ionic strength (/) is a measure of ion concentration, de­ and based on Eq. (1.2) fined by the equation (W] = (1.0 X 10-14)/0.040 = 2.5 X 10- 13 so that where c. is the concentration of ion i, z. is the charge of ' ion i, and L is "the sum ~f." pH = -log[W] = -log(2.5 X 10- 13) = 12.6 = 13 Problem: What is the ionic strength of a O.lM solu­ tion of (NH4 ) 2SO4 ? Solution: Each "molecule" of (NH4) 2SO4 yields two A.3. HE DERSON- H ASSE LBALCH NH; ions and one So~- ion. Hence, EQUATIO N [NHl l = c 1 = 0.2M; z1 = + 1 [So~ - ]= c2 = 0.1M; z2 = - 2 Problem 1: Calculate the pH of a solution made by mix­ 1 I = I/2 ~{ (0.2 X 12) + (0.1 X ( - 2)2]} = 0.3 ing 15.0mlof 1.00 X 10- MK2HP04 and25.0mlof2.00 2 X 10- MKH2P04 . Solution: Molar concentrations of the two salts in the A.2. pH final volume (15.0 + 25.0 = 40.0 ml) are: 1 forK2HP04 : 15.0 X (1.00 X 10- )/40.0 = 0.0375M Problem 1: What is the pH of 0.01 OM HCI, assuming that for KH2P04 : 25.0 X (2.00 X 10- 2)/40.0 = 0.01 25M the HCl is 100% ionized? Substituting these values into the Henderson- Hasselbalch Solution: equation and using pK~ = 7.21 yields [W] = O.OlOM = 1.0 X 10-2M pH = -log[W] = -log(l.O X 10- 2) = 2.0 (0.0375) pH = 7.21 +log (0.0125) = 7.69 Problem 2: What is the pH of 0.020M Ca(OH)2 , as­ suming that it is 100 % ionized? Problem 2: Given that lactic acid (HA = CH3 - Solution: Since each "molecule" of Ca(OH)2 yields CHOH -COOH; A- = CH3 -CHOH - coo- ) has a two OH- ions, pK~ of 3.86, calculate the percent of lactic acid present in 503 504 APPENDIX A its dissociated form (A-) at a pH that is one unit above its (0.400- x) = 0.065 mol ofK2HP04/liter pK~ (i.e., at pH 4.86).
    [Show full text]